IL6 and breast cancer: Furthermore, TAMs activate the NF-κB/STAT3/ERK signaling pathway in tumor cells by secreting pro-inflammatory cytokines such as TNF-α and IL-6, which are responsible for the phosphorylation and activation of ERα, causing endocrine therapy resistance of breast cancer (59).